Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells

Jinsheng Hong1,3, Zhenhuan Zhang2,3, Wenlong Lv1, Mei Zhang2, Chun Chen4, Shanmin Yang2, Shan Li1, Lurong Zhang2, Deping Han4*, Weijian Zhang1,3*

1 Department of Radiation Oncology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China, 2 Department of Radiation Oncology, UF Shands Cancer Center, Gainesville, Florida, United States of America, 3 Division of Radiation Biology, Central Research Lab, First Affiliated Hospital, Fujian Medical University, Fuzhou, China, 4 Department of Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China

Abstract

Icaritin (ICT) is a hydrolytic form of icariin isolated from plants of the genus Epimedium. This study was to investigate the radiosensitization effect of icaritin and its possible underlying mechanism using murine 4T1 breast cancer cells. The combination of icaritin at 3 μM or 6 μM with 6 or 8 Gy of ionizing radiation (IR) in the clonogenic assay yielded an ER (enhancement ratio) of 1.18 or 1.28, CI (combination index) of 0.38 or 0.19 and DRI (dose reducing index) of 2.51 or 5.07, respectively. These strongly suggest that icaritin exerted a synergistic killing (?) effect with radiation on the tumor cells. This effect might relate with bioactivities of ICT: 1) exert an anti-proliferative effect in a dose- and time-dependent manner, which is different from IR killing effect but likely work together with the IR effect; 2) suppress the IR-induced activation of two survival paths, ERK1/2 and AKT; 3) induce the G2/M blockage, enhancing IR killing effect; and 4) synergize with IR to enhance cell apoptosis. In addition, ICT suppressed angiogenesis in chick embryo chorioallantoic membrane (CAM) assay. Taken together, ICT is a new radiosensitizer and can enhance anti-cancer effect of IR or other therapies.

Citation: Hong J, Zhang Z, Lv W, Zhang M, Chen C, et al. (2013) Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells. PLoS ONE 8(8): e71347. doi:10.1371/journal.pone.0071347

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: zwj9090@126.com (WZ); hdp20012004@163.com (DH)

These authors contributed equally to this work.

Introduction

Icaritin (ICT) is a hydrolytic form of icariin purified from the genus Epimedium, a traditional Chinese herbal medicine [1,2,3]. ICT has a broad range of biological activities, including the ability to stimulate neuronal and cardiac differentiation [4,5,6], enhance osteoblast differentiation, suppress osteoclast differentiation and activity [7], prevent steroid-associated osteonecrosis [8], induce apoptosis in human prostatic smooth muscle cells [9], and exert neuroprotective effects [10]. Moreover, it has also been reported that sub-micromolar concentrations of ICT exhibited estrogen-like activity in estrogen receptor-positive breast cancer MCF-7 cells [11] while it inhibited the growth of PC-3 prostate cancer cells [12]. Several studies supported that the ICT exerted an anti-proliferative effect in a variety of tumor cell lines, including human endometrial cancer cells [13] and HepG2 hepatocarcinoma cells [14], as well as chronic myeloid leukemia in vivo [15]. Recently, ICT was reported to induce cell death in activated hepatic stellate cells through mitochondrial-activated apoptosis, and also ameliorate the development of liver fibrosis in rats [16].

Ionizing radiation (IR) therapy is one of mainstream anti-cancer approaches for most types of malignancies, exerting the efficacy on local cancer control and reduces disease recurrence [17]. Extensive efforts have been undertaken by researchers to identify novel radiosensitizing and radioprotective drugs to enhance the therapeutic gain by reducing the radiation dose and side-effect and increasing the tolerance of cancer patients to the treatment IR dose. For example, we have found that triptolide enhanced the anti-tumor effects of irradiation in pancreatic cancer in vivo and in vitro [18,19]. It is unknown whether ICT exerts a synergistic effect with irradiation in any type of cancer. This study explored the ability and mechanism of ICT to enhance the therapeutic effects of IR using the malignant murine 4T1 breast cancer cell line.

Materials and Methods

This study was approved by the relevant institutional review boards for animal study in Fujian Medical University. All experimental procedures were conducted in conformity with institutional guidelines for the care and use of laboratory animals in Fujian Medical University, Fuzhou, China, and conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85–23, revised 1985).

Reagents and Cell Line

ICT (purity of 98.5%) was purchased from Shanghai Usea Biotech Company (China). A stock solution of 100 mM ICT was prepared in dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA) and stored at −20°C. The stock solution was diluted to the appropriate concentrations with culture medium. The final concentration of DMSO was less than 0.1% (vol/vol). The same amount of DMSO was used as the vehicle control throughout this study. The murine breast cancer cell line 4T1 (ATCC, Manassas,
VA, USA) was maintained as monolayers in DMEM medium containing 10% heat-inactivated FBS with 1% penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO2.

**MTT Cell Proliferation Assay**

MTT assay was performed as previously described to determine the survival of cultured cells [20]. The 4T1 cells were seeded into 96-well plates at a density of 5–10×10^3 cells per well, treated with vehicle alone or ICT at the indicated different doses for 24, 48 or 72 h, and then the cell viability was determined by MTT assay. (A) ICT inhibits the growth of 4T1 breast cancer cells in a dose- and time-dependent manner. (B) Representative images of 4T1 cells treated with the indicated concentrations of ICT for 24 h, 48 h or 72 h.

doi:10.1371/journal.pone.0071347.g001

**Figure 1. ICT inhibits the growth of 4T1 breast cancer cells in a dose- and time-dependent manner.** The 4T1 cells were seeded into 96-well plates at a density of 5–10×10^3 cells per well, treated with vehicle alone or ICT at the indicated different doses for 24, 48 or 72 h, and then the cell viability was determined by MTT assay. (A) ICT inhibits the growth of 4T1 breast cancer cells in a dose- and time-dependent manner. (B) Representative images of 4T1 cells treated with the indicated concentrations of ICT for 24 h, 48 h or 72 h.

doi:10.1371/journal.pone.0071347.g001

VA, USA) was maintained as monolayers in DMEM medium containing 10% heat-inactivated FBS with 1% penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO2.

**MTT Cell Proliferation Assay**

MTT assay was performed as previously described to determine the survival of cultured cells [20]. The 4T1 cells were seeded into 96-well tissue culture plates at a density of 5–10×10^3 cells per well, treated with ICT or vehicle for 24, 48 or 72 h, and then incubated with 50 μl of 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) solution for 4 h. The supernatant was discarded, and DMSO was added to each well. Absorbance at 570 nm was measured using a SpectraMax M2 reader (Molecular Devices, CA, USA). Each treatment and time point was triplicate and repeated twice times; the data shown is the representative of three independent experiments. The number of viable cells in the control group or at the initial time point was assigned a relative value of 100%.
Clonogenic Survival Assay for Combination Effect of Icaritin and Radiation

Murine 4T1 cells were treated with vehicle alone, ICT alone (0, 1.5, 3, or 6 μmol/L), radiation alone (0, 2, 4, 6 or 8 Gy) or combination of ICT with radiation. The cells were plated in 60 mm dishes at different densities, based on the stringency of the treatments. The number of cells was adjusted to generate 50 to 200 colonies per dish at each radiation dose. After 14 days, the colonies were stained with crystal violet, and the numbers of colonies (containing ≥50 cells) were counted using Image-Pro® Plus. The surviving fraction (SF) was calculated as the ratio of the number of colonies to the number of cells plated (plating efficiency) in the treatment group, divided by the plating efficiency in the vehicle group. D0 (the incremental dose required for reducing the fraction of colonies to 37%, indicative of single-event killing) was calculated using the formula of the single-hit multi target (SHMT) model [SF = 1 − (1 − e−D/D0)n] (20). SF2, the surviving fraction of exponentially growing cells when irradiated at the clinically relevant dose of 2 Gy; the enhancement ratio (ER); the combination index (CI) and dose reducing index (DRI) were calculated using CompuSyn (Biosoft, Cambridge, UK). Analysis of the synergistic effects of ICT with different doses of radiation was performed using Chou-Talalay’s combination-isobologram and multiple drug-dose effect analysis, as described [21]. A CI <1 and DRI >1 indicated synergistic effects of ICT with IR.

Cell-based ELISA-like Assays for Levels of Phosphorylation of ERK1/2 and AKT

ERK1/2 and AKT are involved in the regulation of proliferation [22]. To further investigate the mechanism of the radiosensitization effect of ICT on 4T1 cells, a cell-based-ELISA-like assay [23,24] was performed to quantify the levels of p-ERK1/2 and p-AKT [25]. The same numbers of 4T1 cells were cultured in triplicate in 96-well plates to 80% confluence; treated with vehicle alone or Icaritin at 3 or 13 μM for 4 or 24 hours, and then irradiated with 0, 1, 4, or 6 Gy. Ten minutes (for p-ERK1/2) or one hour (for p-AKT) later, the cells were fixed with 4% formalin for 5 min followed by 3% H2O2 quenching the endogenous peroxidase for 10 min and blocking with 1% of bovine albumin in 0.1% Tween-20-phosphate buffer for 15 min. After wash 3 times, the rabbit antibodies specifically against phosphorylated ERK1/2 or p-AKT (0.5 μg/ml) were added to the different wells overnight at 4°C followed by HRP-anti-rabbit IgG (0.2 μg/ml) for 1 hour at room temperature and then TMB substrate and stopper and read at A450 using a SpectraMax M2 reader.

Cell Cycle Analysis

After treatment with ICT alone (0, 12.5, 25 μM), IR alone (0, 4, or 6 Gy), or ICT combined with IR for 72 hours, cells were harvested and immediately fixed in 70% alcohol overnight, then stained with PI (Propidium Iodide) solution contained 1% RNase A and 0.3% Triton-X100 for 30 min at room temperature. The samples were then measured by Accuri C6 flow cytometry (BD Biosciences, San Jose, CA) for the fractions of G1, S and G2M phase. The data were analyzed with C6 software. Data was representative of two independent experiments.

Cell Apoptosis Analysis

4T1 cells were exposed to ICT alone (0, 12.5, 25 μM), IR alone (0, 4, or 6 Gy), or combination of ICT with IR for 72 hours, then harvested. After wash with cold PBS, cells were stained with annexin V (Biolegend, San Diego, CA) for 30 minutes and then with PI for 10 minutes according to the manufacture’s instruction. The staining samples then were subjected to Accuri C6 flow cytometry analysis.

Chick Embryo Chorioallantoic Membrane Angiogenesis Assay

The effect of ICT on angiogenesis was investigated using the chick embryo chorioallantoic membrane (CAM) assay. The fertilized eggs were incubated at 37°C for eight days and then divided into groups (8 eggs/group), 100 μl of 0, 10, 20 or 40 μM ICT was added to the top of CAM. After incubation for 3 more days, the CAM of each alive egg was harvested and placed individually in 6 well plate. Images of the blood vessels of each CAM were captured using Motic Images Plus® (MediaCybernetics®, Bethesda, MD, USA). The blood vessel area as a percentage of the total CAM area, blood vessel length and number of branch points were quantified using Image Pro® analysis software (MediaCybernetics®, Bethesda, MD, USA).

Statistical Analysis

All data are expressed as mean ± standard deviation (S.D.). The level of significance between two groups was assessed using Student’s t-test. The difference among three or more groups was assessed with one way ANOVA with SPSS 13 (Chicago, IL, USA). P values <0.05 were considered statistically significant.

Results

ICT Inhibits the Growth of 4T1 Breast Cancer Cells in a Dose- and Time-dependent Manner

To explore the interaction of ICT with IR, we have to know the effect of ICT alone on the testing 4T1 breast cancer cells, which will help to design the combination study with IR. The 4T1 cultured in triplicate in 96 well plates were treated with various concentrations of ICT for 24 h, 48 h or 72 hours, and then the survival cells were measured using the MTT assay. An ICT dose-dependent and time-dependent reduction of 4T1 cells was observed (Fig. 1). The concentration for 50% inhibition (IC50, mean ± SD) was 38 ± 5 μM, 27 ± 3 μM and 13 ± 2 μM at 24 h, 48 h and 72 h, respectively. The data indicated that ICT inhibited the proliferation of 4T1 cells in a dose-dependent and time-dependent manner. To further explore if this effect is universal, we have also examined anti-proliferative effects of ICT on several other human cancer cell lines, including MCF-7 and MDA-MB-

Table 1. Icaritin enhances the radiosensitivity of murine 4T1 breast cancer cells.

| Icaritin | D0 (Gy) | SF2 | ER | CI | DRI |
|----------|---------|-----|----|----|-----|
| 0 μM     | 5.5     | 0.87|    |    |     |
| 1.5 μM   | 4.8     | 0.85| 1.30|4.95|0.20 |
| 3 μM     | 4.7     | 0.83| 1.18|0.39|2.51 |
| 6 μM     | 3.7     | 0.62| 1.28|0.19|5.07 |

D0, incremental dose required for reducing the fraction of colonies to 37%, indicative of single-event killing; SF2, surviving fraction of exponentially growing cells when irradiated at the clinically relevant dose of 2 Gy; ER, enhancement ratio; CI, combination index; DRI, dose reducing index.

*CI <1 and DRI >1 indicate a synergistic cytotoxic effect of icaritin and radiation.

doi:10.1371/journal.pone.0071347.t001
231 breast cancer cells, DU-145 and PC3 prostate cancer cells, as well as B16 murine melanoma cells. All results indicated that ICT suppressed the growth of cancer cells tested (data not shown), suggesting that ICT is likely to inhibit various types of cancer cells.

**ICT Acts Synergistically with Radiation on Suppression of Reproductive Growth of 4T1 Breast Cancer Cells**

The goal of this study is to explore if ICT can be used as a radiosensitizer to radiation, one of the mainstream treatment of various types of cancer. For this, the clonogenic assay was used to determine the extent of reproductive death caused by single treatment of ICT or radiation alone or both in combinations. Since the mouse 4T1 breast cancer cell line is one of the aggressive tumor cell lines that can grow as primary or metastatic tumor in BALB/c mice [26] and is relatively resistant to chemotherapy and radiotherapy [27], it was chosen as the targeted cells. The result (Table 1) demonstrated that when ICT was added to these highly malignant cancer cells, the IR dose required for reducing the fraction of colonies to 37% was dropped from 5.5 Gy to 4.7 Gy (at ICT 3 μM) or 3.7 Gy (at ICT 6 μM), respectively. It was deduced at the clinically relevant dose of 2 Gy, the ICT could reduce the survival fraction from 87% to 83% (at 3 μM) or 62% (at 6 μM), respectively. The treatment enhancement ratio (ER) increased to 1.18 (at 3 μM) or 1.28 (at 6 μM). The combination index (CI) was 0.38 or 0.19 and the dose reducing index (DRI) was 2.51 or 5.07 at ICT 3 μM or 6 μM, respectively. All data (Table 1 and Fig. 2) strongly suggests that ICT could exert a synergistic effect with radiation on aggressive cancer cells. Notably, the concentration of ICT needed for this sensitization effect was relatively low, which might be achievable in vivo.

**ICT Inhibits p-ERK1/2 and p-AKT Signaling**

It is reported that radiation could trigger the activation of multiple signaling pathways, in particular, ERK1/2 and AKT

![Image](image.png)

**Figure 2. ICT acts synergistically with IR in clonogenic assay.** The 4T1 breast cancer cells were treated with vehicle alone, ICT alone (0, 1.5, 3, or 6 μmol/L), radiation alone (0, 2, 4, 6 or 8 Gy) or combination of ICT with radiation. The cells were plated in 60 mm dishes at different densities, based on the stringency of the treatments. After 14 days, the colonies were stained with crystal violet, and the numbers of colonies (containing ≥50 cells) were counted using Image-Pro® Plus. The images represent the synergistic killing effects of ICT and IR on 4T1 cells.

doi:10.1371/journal.pone.0071347.g002
ICT Enhances the Accumulation of G2-M Phase Upon IR

The unique feature of IR is to break DNA of cancer cells, which triggers the activation of P53, a blocker on G2/M phase and induces the apoptosis [29]. To determine if ICT could enhance this G2/M blockage, the 4T1 cells were treated with different doses of ICT (0, 12.5 and 25 μM) or IR (0, 4 or 6 Gy), or ICT combined with IR for 72 hours, and then the fractions of cells in different cycles were assessed with flow cytometry. Results (Fig. 4) showed that while IR (4 or 6 Gy) alone could shift the G2/M phase (indicated as M2), the combination of ICT 12.5 μM or 4 Gy IR with 25 μM ICT is the case, the 4T1 cells were treated with ICT (at 0, 12.5 or 25 μM) or IR (0, 4 or 6 Gy), or ICT combined with IR for 72 hours, and then the fractions of cells in different cycles were assessed with flow cytometry. Results (Fig. 4) showed that while IR (4 or 6 Gy) alone could shift the G2/M phase (indicated as M2), the combination of ICT could all be inhibited by ICT to their basal levels. It is clear that via suppressing IR-induced “rescue/survival” signaling, ICT acts together with IR to enhance the reproductive killing effect as demonstrated in the clonogenic assay (Table 1 and Fig. 2).

Combination of ICT and IR Increases Cell Apoptosis

The cells blocked in G2-M phase unable to pass into G0G1 phase are likely to take the path of apoptosis. To determine if this is the case, the 4T1 cells were treated with ICT (at 0, 12.5 or 25 μM), or radiation at (0, 4 or 6 Gy), or ICT combined with radiation. 72 hours after treatment, the cells were harvested and stained with Annexin V and PI for three subpopulations: apoptotic cells (Annexin V positive), early dead cells (Annexin V and PI double positive) and dead cells (PI positive). The results (Fig. 5) showed that the while single treatment could increase three subsets of sick cells, the combined treatment could promote more cancer cells into these three subsets, especially when IR 4 or 6 Gy combined with ICT 12.5 μM or 4 Gy IR with 25 μM ICT (P<0.05). ICT with IR indeed acts together to enhance the killing effect on cancer cells.

ICT Inhibits Angiogenesis in the Chick Embryo Chorioallantoic Membrane (CAM)

To kill the tumor, besides to knock-down their reproductive ability, the blocking of their blood supply is also crucial. To determine if ICT could not only enhance the IR effect, but also suppress the angiogenesis, CAM assay was performed in 8 day fertilized eggs. Figure 6A showed that the newly-formed vessels were reduced in an ICT dose-dependent manner. Quantitative analysis of properties of angiogenesis demonstrated that ICT significantly decreased the vessel area (Fig. 4B), vessel length (Fig. 4C) and number of dendrites (Fig. 4D) in a dose-dependent manner, suggesting that ICT possesses the capacity for anti-angiogenesis, which is likely to help the tumor shrinkage in vivo.

Discussion

This study is to explore the synergistic effect of ICT with radiation. For the first time, we demonstrate that ICT enhances the radiosensitivity of the highly malignant 4T1 breast cancer cells. ICT is capable to reduce IR dose that needed to kill cancer cells (D0 reduced) and allow 2 Gy IR to kill more cancer cells (SF2 reduced). Two key criteria for synergistic effect are met: [28], to promote some cancer cells growth after the stress of IR. To explore if ICT could counteract the undesirable survival signaling that helps cancer cells to escape the death and cancel-out the IR killing effect, the effect of ICT on IR-induced activation of p-ERK1/2 and p-AKT was studied with cell-based ELISA-like assay [23,24]. Since two signal paths have its own sensitivity to ICT and its own phosphorylation timing upon IR stress, the assays were performed differently. For phospho-ERK1/2 assay, the 4T1 cells were treated with ICT for 4 hr and harvested 10 min after IR, while for phospho-AKT assay, the 4T1 cells were treated with ICT for 24 hr and harvested 1 hr after IR. Figure 3 demonstrated that the IR at 1, 4, 6 Gy was able to trigger the phosphorylation of ERK1/2 and AKT, which could all be inhibited by ICT to their basal levels. It is clear that via suppressing IR-induced “rescue/survival” signaling, ICT acts together with IR to enhance the reproductive killing effect as demonstrated in the clonogenic assay (Table 1 and Fig. 2).

ICT inhibits irradiation-induced phosphorylation of ERK1/2 and AKT.

(A) p-ERK1/2 assay. 4T1 cells were treated with vehicle alone or Icaritin at 13 μM for 4 hr, and then irradiated with 0, 1, 4, or 6 Gy. Ten minutes later, the cells were fixed with 4% formalin for 5 min and subjected to an in-plate ELISA-like test with rabbit anti-phosphorylated ERK followed by horseradish peroxidase-anti-rabbit and a TMB substrate and A500 reading. (B) p-AKT assay: 4T1 cells were treated with vehicle alone or Icaritin at 3 μM for 24 hr, and then irradiated with 0, 1, 4, or 6 Gy; One hour later, the cells were fixed with 4% formalin and subjected to an in-plate ELISA-like assay using rabbit anti-phosphorylated AKT as first antibody followed by the same method as detection for phosphorylated ERK1/2. repores *p<0.05; **represents p<0.01; NS means not significant.

doi:10.1371/journal.pone.0071347.g003

[28], to promote some cancer cells growth after the stress of IR. To explore if ICT could counteract the undesirable survival signaling that helps cancer cells to escape the death and cancel-out the IR killing effect, the effect of ICT on IR-induced activation of p-ERK1/2 and p-AKT was studied with cell-based ELISA-like assay [23,24]. Since two signal paths have its own sensitivity to ICT and its own phosphorylation timing upon IR stress, the assays were performed differently. For phospho-ERK1/2 assay, the 4T1 cells were treated with ICT for 4 hr and harvested 10 min after IR, while for phospho-AKT assay, the 4T1 cells were treated with ICT for 24 hr and harvested 1 hr after IR. Figure 3 demonstrated that the IR at 1, 4, 6 Gy was able to trigger the phosphorylation of ERK1/2 and AKT, which could all be inhibited by ICT to their basal levels. It is clear that via suppressing IR-induced “rescue/survival” signaling, ICT acts together with IR to enhance the reproductive killing effect as demonstrated in the clonogenic assay (Table 1 and Fig. 2).
Figure 4. Accumulation of G2-M cell population after combination of ICT and IR. 4T1 cells were treated with ICT (0, 12.5, 25 μM), IR (0, 4, or 6 Gy), or ICT combined with IR. 72 hours after treatment, the cells were harvested and subjected to flow cytometry. (A) FCM images represent the fraction of cells in G0G1 phase (M1), S phase (M2) and G2-M phase (M3) after different single or combined treatment. (B) Bar graphs represent the percentage of cells in three different phases. 

doi:10.1371/journal.pone.0071347.g004
or accumulate in the G2/M phase, the more cells could die due to phase (Fig. 4 A and B). The more cells abnormally are blocked-in to IR killing. ICT could enhance the cell accumulation in G2/M apoptosis.

ICT combined with IR. 72 hours after treatment, the cells were harvested and stained with Annexin V and PI. Combination of ICT and IR enhanced a radiosensitizer.

The internal apoptosis or external IR killing. The molecules damage the cancer cells through these two different paths, which respectively, the combined use of IR and ICT would increasingly clean-up these mutated cells to ensure that the repopulating cells are normal and healthy. Our data (Fig. 5) shows that ICT could block the activation (phosphorylation) of ERK1/2 and AKT and disrupt the protection process (Fig. 3). Therefore, more reproductive death is observed (Table 1 and Fig. 2).

First, IR is an overwhelming physic insult to cells. To counteract the IR stress, some cancer cells instantly activate their own survival signaling, such as ERK1/2 and AKT paths, which might accelerate the repopulation and compensate the lost cells. The ICT could block the activation (phosphorylation) of ERK1/2 and AKT and disrupt the protection process (Fig. 3). Therefore, more reproductive death is observed (Table 1 and Fig. 2).

Secondly, it is well-known that IR could activate P53 and push cell staying G2/M phase then subject to internally triggered apoptosis. In addition, the cells in G2/M phase are most sensitive to IR killing. ICT could enhance the cell accumulation in G2/M phase (Fig. 4 A and B). The more cells abnormally are blocked-in or accumulate in the G2/M phase, the more cells could die due to the internal apoptosis or external IR killing. The molecules involved in this process might include these in the P53, ERK1/2 and AKT paths. This might be the major reason that ICT can be a radiosensitizer.

Thirdly, IR causes cell death mainly via necrosis and apoptosis. When IR dose is high enough, it strongly disrupts the cellular macromolecules, including structure protein, functional lipids, enzymes and DNA, leading directly to necrosis. However, if the IR dose is low and cell has the capacity to repair the damage, it can have two scenarios: (1) fidelity repair as all repaired molecules carrying out the function normally, in which cells are fully recovered; and (2) infidelity repair as some of molecules mutated with abnormal functions, which could trigger the apoptosis to clean-up these mutated cells to ensure that the repopulating cells are normal and healthy. Our data (Fig. 5) shows that ICT could also induce both necrosis and apoptosis in a dose-dependent manner. Since the induction of necrosis and apoptosis by IR and ICT utilizes two different mechanisms, a physic and chemic insult, respectively, the combined use of IR and ICT would increasingly damage the cancer cells through these two different paths, which makes the insulted cancer cells even more difficult to repair damages from each insult, leading to a synergistic killing effect on the treated cells as showed in Table 1 and Fig. 2.

There are several studies exploring the action mechanism of ICT. Some of them are consistent with our data. For example, ICT treated human MCF-7 and MDA-MB-453 breast cancer cells could also induce cancer cell arrested in G2/M phase and cell death [21], similar to what we found in mouse 4T1 breast cancer cells. Other molecules are also involved in ICT action, such as upregulating retinoblastoma protein (Rb), p27Kip1 and p16Ink4a protein expression, downregulating phosphorylated retinoblastoma protein (pRb), Cyclin D1 and CDK4 protein expression, reducing mitochondrial transmembrane potential [11,12] and suppressing JNK activation [14].

Clinical studies have demonstrated the benefits of adjuvant radiotherapy for improving disease-free survival, overall survival and local control, and reducing disease recurrence after surgical resection in breast cancer patients [17]. However, radiotherapy is associated with side effects, including epidermitis [25], lung fibrosis [32] and an increased risk of cardiovascular disease [33]. The discovery of novel agents which sensitize malignant cells to radiation would increase tumor response, while minimizing toxicity to the surrounding organs by lowering the effective therapeutic dose. ICT at a concentration of 3 μM to 6 μM enhanced the radiosensitivity of 4T1 cells and potentially lowering the IR dose to achieve the same killing effect at higher IR dose, and thereby reducing the IR side effect.

Another major finding of this study is that ICT significantly inhibited angiogenesis in the CAM assay. Since the angiogenesis plays an important role in the growth and progression of solid tumors [34], the anti-angiogenesis effect would further enhance the ICT anti-tumor effect by its own or combination with IR in vivo.

In summary, this study demonstrates that ICT synergistically acts with IR to enhance the reproductive death of highly malignant 4T1 breast cancer cells via suppressing IR-induced activation of ERK1/2 and AKT survival paths, enhancing the cancer cell G2/M arrest and apoptosis. These results suggest that pharmacological approaches using ICT as a new radiosensitizer in
combination with IR could increase the effectiveness of IR cancer treatment, which could have important implications for the development of novel radiotherapy strategies.

Author Contributions
Conceived and designed the experiments: JH ZZ WL MZ CC SY SL LZ DH WZ. Performed the experiments: JH SY ZZ MZ SL WL DH. Analyzed the data: JH LZ DH WZ. Contributed reagents/materials/analysis tools: LZ ZZ WZ. Wrote the paper: JH WZ LZ.

References
1. Wu H, Lien EJ, Lien LL (2003) Chemical and pharmacological investigations of Epimedium species: a survey. Prog Drug Res 60: 1–57.
2. Shen P, Guo BL, Gong Y, Hong DY, Hong Y, et al. (2007) Taxonomic, genetic, chemical and estrogenic characteristics of Epimedium species. Phytochemistry 68: 1449–1458.
3. Chen Y, Zhao YH, Jia XB, Hu M (2008) Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Pharm Res 25: 2190–2199.
4. Zhu DY, Zhang XN, Du Y (2007) Directed differentiation of mouse embryonic stem cells into neuronal cells induced by icaritin in vitro. Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 217–223.
5. Wang Z, Wang H, Wu J, Zhu D, Zhang X, et al. (2009) Enhanced co-expression of beta-tubulin III and choline acetyltransferase in neurons from mouse embryonic stem cells promoted by icaritin in an estrogen receptor-independent manner. Chem Biol Interact 179: 375–385.
6. Wu YB, Zhu DY, Hu Y, Wang ZQ, Liu J, et al. (2008) Reactive oxygen species involved in prenylflavonoids, icarin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J Cell Biochem 103: 1356–1358.
7. Huang H, Liang M, Zhang X, Zhang C, Shen Z, et al. (2007) Simultaneous determination of nine flavonoids and qualitative evaluation of Herba Epimedii by high performance liquid chromatography with ultraviolet detection. J Sep Sci 30: 3207–3213.
8. Zhang G, Qin L, Sheng H, Wang XL, Wang YX, et al. (2009) A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombus and lipid-deposition in a dose-dependent manner. Bone 44: 345–356.
9. Chen MF, Qi L, Li Y, Zou XB, Dai YQ, et al. (2010) Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner. Amino Acids 38: 1505–1513.
10. Wang Z, Zhang X, Wang H, Qi L, Lou Y (2007) Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuroscience 145: 911–922.

11. Wang ZQ, Lou YJ (2004) Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol 504: 147–153.

12. Huang X, Zhu D, Lou Y (2007) A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol 564: 26–36.

13. Tong JS, Zhang QH, Huang X, Fu XQ, Qi ST, et al. (2011) Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One 6: e16781.

14. He J, Wang Y, Duan F, Jiang H, Chen MF, et al. (2010) Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor. Planta Med 76: 1834–1839.

15. Zhu J, Li Z, Zhang G, Meng K, Kuang W, et al. (2011) Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS One 6: e23720.

16. Li J, Liu P, Zhang R, Cao L, Qian H, et al. (2011) Icaritin induces cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorates the development of liver fibrosis in rats. J Ethnopharmacol 137: 714–723.

17. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, et al. (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol 25: 3259–3265.

18. Yang S, Chen J, Guo Z, Xu XM, Wang L, et al. (2003) Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2: 65–72.

19. King TC, Estalilla OG, Safran H (1999) Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin Radiat Oncol 9(2 Suppl 1): 4–11.

20. Lo¨brich M, Jeggo PA (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 7 (11): 861–9.

21. Ohri N, Dicker AP, Lawrence YR (2012) Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys. 1; 83(1): 385–93.

22. Hoening MJ, Botma A, Alemam BM, Baaijens MH, Bartelink H, et al. (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99: 363–375.

23. Hooning MJ, Botma A, Alemam BM, Baaijens MH, Bartelink H, et al. (2007) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.